MA58104B1 - Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine - Google Patents
Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamineInfo
- Publication number
- MA58104B1 MA58104B1 MA58104A MA58104A MA58104B1 MA 58104 B1 MA58104 B1 MA 58104B1 MA 58104 A MA58104 A MA 58104A MA 58104 A MA58104 A MA 58104A MA 58104 B1 MA58104 B1 MA 58104B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- ylmethanamine
- oxetane
- salt
- compound
- Prior art date
Links
- QDEFNAHLCTUWAH-UHFFFAOYSA-N oxetan-2-ylmethanamine Chemical compound NCC1CCO1 QDEFNAHLCTUWAH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
L'invention concerne un procédé et un intermédiaire pour la préparation d'un composé de formule i, ou d'un sel de celui-ci.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946146P | 2019-12-10 | 2019-12-10 | |
| PCT/US2020/063546 WO2021118906A1 (fr) | 2019-12-10 | 2020-12-07 | Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA58104B1 true MA58104B1 (fr) | 2024-05-31 |
Family
ID=74003942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58104A MA58104B1 (fr) | 2019-12-10 | 2020-12-07 | Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20230013840A1 (fr) |
| EP (1) | EP4073051B1 (fr) |
| JP (1) | JP7292517B2 (fr) |
| KR (1) | KR102635237B1 (fr) |
| CN (1) | CN114728923A (fr) |
| AU (1) | AU2020401539B2 (fr) |
| BR (1) | BR112022008892A2 (fr) |
| CA (1) | CA3160419A1 (fr) |
| CL (1) | CL2022001511A1 (fr) |
| CO (1) | CO2022008127A2 (fr) |
| DK (1) | DK4073051T3 (fr) |
| EC (1) | ECSP22046595A (fr) |
| ES (1) | ES2975599T3 (fr) |
| FI (1) | FI4073051T3 (fr) |
| HR (1) | HRP20240343T1 (fr) |
| IL (1) | IL292707A (fr) |
| LT (1) | LT4073051T (fr) |
| MA (1) | MA58104B1 (fr) |
| MD (1) | MD4073051T2 (fr) |
| MX (1) | MX2022006984A (fr) |
| PE (1) | PE20230183A1 (fr) |
| PL (1) | PL4073051T3 (fr) |
| PT (1) | PT4073051T (fr) |
| RS (1) | RS65238B1 (fr) |
| SI (1) | SI4073051T1 (fr) |
| UA (1) | UA127884C2 (fr) |
| WO (1) | WO2021118906A1 (fr) |
| ZA (1) | ZA202205170B (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208140B2 (en) * | 2003-02-19 | 2007-04-24 | Schering Aktiengesellschaft | Trimeric macrocyclic substituted benzene derivatives |
| MD4557C1 (ro) * | 2011-05-06 | 2018-10-31 | Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu |
| US9376409B2 (en) * | 2012-05-09 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
| JP6637641B1 (ja) * | 2016-12-16 | 2020-01-29 | ファイザー・インク | Ｇｌｐ−１受容体アゴニストおよびその使用 |
| CN109265389B (zh) * | 2018-08-31 | 2020-08-18 | 南京富润凯德生物医药有限公司 | 2-(氨基甲基)-1-氧杂-7-氮杂螺[3.5]壬烷衍生物、中间体及其制备方法 |
-
2020
- 2020-12-07 MX MX2022006984A patent/MX2022006984A/es unknown
- 2020-12-07 MD MDE20221148T patent/MD4073051T2/ro unknown
- 2020-12-07 JP JP2022534655A patent/JP7292517B2/ja active Active
- 2020-12-07 PL PL20829133.6T patent/PL4073051T3/pl unknown
- 2020-12-07 MA MA58104A patent/MA58104B1/fr unknown
- 2020-12-07 RS RS20240243A patent/RS65238B1/sr unknown
- 2020-12-07 HR HRP20240343TT patent/HRP20240343T1/hr unknown
- 2020-12-07 EP EP20829133.6A patent/EP4073051B1/fr active Active
- 2020-12-07 WO PCT/US2020/063546 patent/WO2021118906A1/fr active Application Filing
- 2020-12-07 CN CN202080082957.9A patent/CN114728923A/zh active Pending
- 2020-12-07 BR BR112022008892A patent/BR112022008892A2/pt active IP Right Grant
- 2020-12-07 DK DK20829133.6T patent/DK4073051T3/da active
- 2020-12-07 CA CA3160419A patent/CA3160419A1/fr active Pending
- 2020-12-07 UA UAA202201389A patent/UA127884C2/uk unknown
- 2020-12-07 AU AU2020401539A patent/AU2020401539B2/en active Active
- 2020-12-07 US US17/779,447 patent/US20230013840A1/en active Pending
- 2020-12-07 IL IL292707A patent/IL292707A/en unknown
- 2020-12-07 PE PE2022001046A patent/PE20230183A1/es unknown
- 2020-12-07 KR KR1020227018626A patent/KR102635237B1/ko active IP Right Grant
- 2020-12-07 SI SI202030381T patent/SI4073051T1/sl unknown
- 2020-12-07 LT LTEPPCT/US2020/063546T patent/LT4073051T/lt unknown
- 2020-12-07 FI FIEP20829133.6T patent/FI4073051T3/fi active
- 2020-12-07 ES ES20829133T patent/ES2975599T3/es active Active
- 2020-12-07 PT PT208291336T patent/PT4073051T/pt unknown
-
2022
- 2022-05-10 ZA ZA2022/05170A patent/ZA202205170B/en unknown
- 2022-06-08 CL CL2022001511A patent/CL2022001511A1/es unknown
- 2022-06-08 CO CONC2022/0008127A patent/CO2022008127A2/es unknown
- 2022-06-10 EC ECSENADI202246595A patent/ECSP22046595A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220097941A (ko) | 2022-07-08 |
| FI4073051T3 (fi) | 2024-03-28 |
| EP4073051B1 (fr) | 2024-02-07 |
| RS65238B1 (sr) | 2024-03-29 |
| AU2020401539B2 (en) | 2023-06-01 |
| JP7292517B2 (ja) | 2023-06-16 |
| US20230013840A1 (en) | 2023-01-19 |
| ECSP22046595A (es) | 2022-07-29 |
| PE20230183A1 (es) | 2023-02-01 |
| CA3160419A1 (fr) | 2021-06-17 |
| SI4073051T1 (sl) | 2024-04-30 |
| CN114728923A (zh) | 2022-07-08 |
| CL2022001511A1 (es) | 2023-01-20 |
| HRP20240343T1 (hr) | 2024-05-24 |
| BR112022008892A2 (pt) | 2022-08-23 |
| ES2975599T3 (es) | 2024-07-09 |
| JP2023504581A (ja) | 2023-02-03 |
| MD4073051T2 (ro) | 2024-08-31 |
| MX2022006984A (es) | 2022-07-13 |
| ZA202205170B (en) | 2024-09-25 |
| DK4073051T3 (da) | 2024-02-26 |
| EP4073051A1 (fr) | 2022-10-19 |
| IL292707A (en) | 2022-07-01 |
| LT4073051T (lt) | 2024-03-12 |
| PL4073051T3 (pl) | 2024-05-20 |
| PT4073051T (pt) | 2024-02-21 |
| CO2022008127A2 (es) | 2022-06-10 |
| AU2020401539A1 (en) | 2022-06-16 |
| WO2021118906A1 (fr) | 2021-06-17 |
| UA127884C2 (uk) | 2024-01-31 |
| KR102635237B1 (ko) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52948B1 (fr) | Composés | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
| MA46337B1 (fr) | Composé de pyridine | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA40301A1 (fr) | Composés indolecarboxamides utiles comme inhibiteurs de kinase | |
| MA42341B2 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| MA33840B1 (fr) | Nouveau composé de spiropipéridine | |
| FR3087439B1 (fr) | Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone) | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA40895B1 (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA33662B1 (fr) | Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| ZA202201503B (en) | Urea compound for antagonizing lpa1 receptor | |
| MA39983B1 (fr) | Dérivés de carboxamide | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MA53370B1 (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| MA50093B1 (fr) | Composé pentacyclique | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| EP4289844A3 (fr) | Procédé de préparation de palbociclib |